Combines two proven blockbuster monoclonal antibodies: Perjeta® (pertuzumab) and Herceptin® (trastuzumab) in single vial for subcutaneous administration Is also the world’s first subcutaneous therapy for breast cancer that offers faster, more comfortable administration of Perjeta and Herceptin under the skin in just minutes, compared